Articles related to GLP-1 RECEPTOR AGONISTS

Foundayo will be available via LillyDirect beginning April 6, with widespread availability through retail pharmacies and telehealth providers occurring soon after.

Reductions in lean body mass are likely concentrated in non-contractile components rather than reflecting a clear decline in muscle function.

“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop.” – Senior study author Ziyad Al-Aly, MD; Washington University School of Medicine

The approval was based on data from the randomized, double-blinded, parallel-group phase 3b STEP UP trial, which enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2, without diabetes.

“The increased risk of NAION with Wegovy is due to the higher dosage of semaglutide…the difference between the two dosages and the rates of NAION may indicate a dose-dependent increase in risk.” – Benjamin Bert, MD

“Selecting a GLP-1 receptor agonist over another antihyperglycemic drug could plausibly confer ancillary benefit” in patients at high risk for or living with an SUD. — Study authors